


IN THE CLAIMS

Please amend the claims as follows.

1. (Currently amended) A compound of Formula (I), ~~including an enantiomer, stereoisomer, rotomer, tautomer and/or prodrug thereof, or a pharmaceutical composition or a pharmaceutically acceptable salt thereof, the compound having the formula (I):~~




where,

- (a) R^1 and R^2 are, independently of one another, each a C_{1-15} alkyl group, branched or straight chain, ~~with or without unsubstituted or substituted with one or more substituents, a C_{2-15} alkenyl group, branched or straight chain, with or without unsubstituted or substituted with one or more substituents, a C_{2-15} alkynyl group, branched or straight chain, with or without unsubstituted or substituted with one or more substituents, a C_{3-15} cycloalkyl group, with or without unsubstituted or substituted with one or more substituents, an arylalkyl group, with or without unsubstituted or substituted with one or more substituents, an aryl group, with or without unsubstituted or substituted with one or more substituents, a heteroaryl group, with or without unsubstituted or substituted with one or more substituents, - OR^5 , - $COOR^5$, - $C(O)R^5$ or - $C(O)N(R^5)_2$, where, R^5 is a hydrogen atom or a hydrocarbon radical,~~

~~with or without unsubstituted or substituted with one or more substituents, or one of R¹ and R² is a hydrogen atom and the other one of R¹ and R² is defined the same as above;~~

(b) R³ is an aryl group, ~~with or without unsubstituted or substituted with one or more substituents, a heteroaryl group, with or without unsubstituted or substituted with one or more substituents, or a heterocyclic group having 1 to 3 heteroatoms fused to a 5- or 6-membered aryl ring, with or without unsubstituted or substituted with one or more substituents, with the proviso that R³ is not an aryl group substituted at its para position with a -Y-aryl group, where, Y is a carbon-carbon single bond, -CO- C(O)-, -O-, -S-, -N(R²¹)-, -CON(R²²)-, -C(O)N(R²²)-, -N(R²²)CO- N(R²²)C(O)-, -OCH₂-, -CH₂O-, -SCH₂-, -CH₂S-, -NHC(R²³)(R²⁴)- N(H)C(R²³)(R²⁴)-, -N(R²³)S(O₂)-, -SO₂NR²³-, -S(O₂)N(R²³)-, -(R²³)(R²⁴)NH- (R²³)(R²⁴)N(H)-, -CH=CH-, -CF=CF-, -CH=CF-, -CF=CH-, -CH₂CH₂-, -CF₂CF₂-,~~



where,

R^{21} is a hydrogen atom or a $-CO(C_{1-4}$ alkyl), C_{1-6} alkyl, allyl, C_{3-6} cycloalkyl, phenyl or benzyl group;

R^{22} is a hydrogen atom or a C_{1-6} alkyl group;


R^{23} is a hydrogen atom or a C_{1-5} alkyl, aryl or $-CH_2$ -aryl group;

R^{24} is a hydrogen atom or a C_{1-4} alkyl group;

R^{25} is a hydrogen atom or a C_{1-8} alkyl, C_{1-8} perfluoroalkyl, C_{3-6} cycloalkyl, phenyl or benzyl group;

R^{26} is a hydrogen atom or a C_{1-6} alkyl, C_{3-6} cycloalkyl, phenyl or benzyl group;

R^{27} is $-NR^{23}R^{24}$, $-OR^{24}$, $-NHCONH_2$, $-NHCSNH_2$,




and

R^{28} and R^{29} are, independently of one another, each a C_{1-4} alkyl group or, taken together with each other, a $-(CH_2)_q$ group, where q is 2 or 3; and

(c) ~~R⁴ is a C₃₋₁₅-cycloalkyl group, with or without one or more substituents, or a C₃₋₁₅-cycloalkenyl group, with or without one or more substituents, or a heterocycloalkyl group of 3 to 15 members with or without unsubstituted or substituted with one or more substituents;~~

wherein, the one or more substituents for all the groups are chemically-compatible and are, independently of one another, each an: alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, arylalkyl, alkylaryl, aryl, heteroaryl, heterocycloalkyl, hydroxyalkyl, arylalkyl, aminoalkyl, haloalkyl, thioalkyl, alkylthioalkyl, carboxyalkyl, imidazolylalkyl, indolylalkyl, mono-, di- and trihaloalkyl, mono-, di- and trihaloalkoxy, amino, alkylamino, dialkylamino, alkoxy, hydroxy, halo, nitro, oximino, -COOR⁵⁰, -COR⁵⁰, -SO₀₋₂R⁵⁰, -SO₂NR⁵⁰R⁵¹, NR⁵²SO₂R⁵⁰, =C(R⁵⁰R⁵¹), =N-OR⁵⁰, =N-CN, =C(halo)₂, =S, =O, -CON(R⁵⁰R⁵¹), -OCOR⁵⁰, -OCON(R⁵⁰R⁵¹), -N(R⁵²)CO(R⁵⁰), -N(R⁵²)COOR⁵⁰ or -N(R⁵²)CON(R⁵⁰R⁵¹) group, where:

R⁵⁰, R⁵¹ and R⁵² are, independently of one another, each a hydrogen atom or a branched or straight-chain, optionally substituted, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₄₋₆ heterocycloalkyl, heteroaryl or aryl group, or R⁵⁰ and R⁵¹ are joined together to form a carbocyclic or heterocyclic ring system, or R⁵⁰, R⁵¹ and R⁵² are, independently of one another, each:



where,

R^{40} and R^{41} are, independently of one another, each a hydrogen atom or a branched or straight-chain, optionally substituted, alkyl, cycloalkyl, heterocycloalkyl, halo, aryl, imidazolylalkyl, indolylalkyl, heteroaryl, arylalkyl, arylalkoxy, heteroarylalkyl, heteroarylalkoxy, aminoalkyl, haloalkyl, mono-, di- or trihaloalkyl, mono-, di- or trihaloalkoxy, nitro, cyano, alkoxy, hydroxy,

amino, phosphino, phosphate, alkylamino, dialkylamino, formyl, alkylthio, trialkylsilyl, alkylsulfonyl, arylsulfonyl, alkylsulfinyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, morpholino, thioalkyl, alkylthioalkyl, carboxyalkyl, oximino, -COOR⁵⁰, -COR⁵⁰, -SO₀₋₂R⁵⁰, -SO₂NR⁵⁰R⁵¹, -NR⁵²SO₂R⁵⁰, -CON(R⁵⁰R⁵¹), -OCON(R⁵⁰R⁵¹), -N(R⁵²)CO(R⁵⁰), -N(R⁵²)COOR⁵⁰, -N(R⁵²)CON(R⁵⁰R⁵¹) or -OCONR⁵⁰ group, where, R⁵⁰, R⁵¹ and R⁵² are defined the same as above;

R⁴² is a hydrogen atom or a branched or straight-chain, optionally substituted, alkyl, alkenyl, arylalkyl or acyl group; and

R⁴³ is a hydrogen atom or a branched or straight-chain, optionally substituted, alkyl or aryl group;

wherein, the optional substituents are defined the same as above for the one or more substituents.

2. (Currently amended) The compound ~~or pharmaceutical composition~~ according to claim 1, where, R¹ is an alkyl or aryl group, with or without the one or more substituents.
3. (Currently amended) The compound ~~or pharmaceutical composition~~ according to claim 2, where, R¹ is a methyl, ethyl or benzyl group, with or without the one or more substituents.
4. (Currently amended) The compound ~~or pharmaceutical composition~~ according to claim 1, where, R² is an alkyl group, with or without the one or more substituents.


5. (Currently amended) The compound or pharmaceutical composition according to claim 4, where, R² is a methyl, ethyl, iso-butyl or hydroxyethyl group, with or without the one or more substituents.
6. (Currently amended) The compound or pharmaceutical composition according to claim 1, where, R³ is an aryl group, with or without the one or more substituents.
7. (Currently amended) The compound or pharmaceutical composition according to claim 6, where, R³ is a hydroxyaryl, alkoxyaryl or aminosulfonylaryl group, with or without the one or more substituents.
8. (Currently amended) The compound or pharmaceutical composition according to claim 7, where, the hydroxyaryl, alkoxyaryl or aminosulfonylaryl group for R³ is substituted with at least one halogen atom on the aryl ring.
9. (Currently amended) The compound or pharmaceutical composition according to claim 1, where, R⁴ is a cycloalkyl or heterocycloalkyl group, with or without the one or more substituents.
10. (Currently amended) The compound or pharmaceutical composition according to claim 9, where, R⁴ is a cyclohexyl, hydroxycyclopentyl or tetrahydropyranyl group, with or without the one or more substituents.
11. (Currently amended) The compound or pharmaceutical composition according to claim 1, where, R¹ is a methyl or ethyl group, R² is a methyl,

ethyl or hydroxyethyl group, R³ is a 3-chloro-4-hydroxyphenyl, 3-bromo-4-hydroxyphenyl, 3-chloro-4-methoxyphenyl, 3-bromo-4-methoxyphenyl, or 4-aminosulfonylphenyl group and R⁴ is a cyclohexyl, tetrahydropyranyl or 2(R)-hydroxy-1(R)-cyclopentyl group.

12. (Currently amended) The compound or pharmaceutical composition according to claim 1,
where, R¹ is an alkyl or aryl group, with or without the one or more substituents, R² is an alkyl group, with or without the one or more substituents, and R³ is a 4-hydroxyphenyl, 3-chloro-4-hydroxyphenyl, 3-bromo-4-hydroxyphenyl, 4-methoxyphenyl, 3-chloro-4-methoxyphenyl, 3-bromo-4-methoxyphenyl, 4-aminosulfonylphenyl, 3-chloro-4-aminosulfonylphenyl or 3-bromo-4-aminosulfonylphenyl group.


13-21. (Canceled)

22. (Currently amended) The compound or pharmaceutical composition according to claim 1, which is:



23.(Currently amended) The compound or pharmaceutical composition

according to claim 1, which is:



24.(Original) The compound or pharmaceutical composition according to claim

1, which has a PDE V IC₅₀ within the range of up to about 5 nM.

25.(Original) The compound or pharmaceutical composition according to claim


1, which has a ratio of PDE VI IC₅₀/ PDE V IC₅₀ of > about 140.

26.(Original) The compound or pharmaceutical composition according to claim

1, which has a PDE V IC₅₀ within the range of up to about 5 nM and a ratio of PDE VI IC₅₀/ PDE V IC₅₀ of > about 140.

27. (Currently amended) The compound or pharmaceutical composition

according to claim 1, where, R^4 is:



where,

R^1 , R^2 and R^3 , independently of one another, are each defined the same as above for the compound of formula (I);

R^9 is a hydrogen atom or an optionally substituted, oximino, carboxyalkyl, C_{1-6} alkoxy C_{1-6} alkyl group, aryloxy C_{1-6} alkyl, C_{3-6} cycloalkoxy C_{1-6} alkyl, heteroaryloxy C_{1-6} alkyl, $-COOH$, ester, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{3-6} heterocyclic, hydroxy C_{1-6} alkyl, aryl or heteroaryl group;

R^{10} and R^{11} are substituents on the same or different carbon atoms of the ring and, independently of one another, are each:

- (a) defined the same as above for R^9 ;
- (b) a hydroxy group or an ester group derived from a hydroxy group with a (i) C_{1-6} carboxylic acid; (ii) C_{3-6} cycloalkyl C_{1-6} carboxylic acid; (iii) aryl C_{1-6} carboxylic acid; or (iv) heteroaryl C_{1-6} carboxylic acid group; or
- (c) a C_{1-6} alkoxy, amino, C_{1-6} mono- or dialkylamino, C_{1-6} alkylacylamino, C_{1-6} alkylsulfonylamino or

~~-NHCON(R¹⁴)₂ group, with or without unsubstituted or substituted with one or more substituents, where R¹⁴ is a hydrogen atom or an optionally substituted, C₁₋₆ alkyl or aryl group, or~~

R¹⁰ and R¹¹, taken together with each other and, optionally, with one or more carbon and/or hetero atoms of the ring, form an optionally substituted, spiro- or linearly fused, bi- or tri-cyclic ring system of from 8 to 12 members, including from 0 to 4 hetero atoms;

m and n, independently of one other, are each from 1 to 3; and

X is a chemically-compatible group, which is $-C(R^{10}R^{11})-$,

$-S(O)_y$, $-O-$ $-N(R^{60})-$, where:

~~R¹⁰ and R¹¹ are defined the same as above;~~

y is from 0 to 2; and

R⁶⁰ is a hydrogen atom or an optionally substituted, C₁₋₈ alkyl, C₁₋₈ alkynyl, C₁₋₈ alkenyl, C₃₋₈ cycloalkyl, aryl, heteroaryl, C₄₋₈ heterocycloalkyl, COR⁶¹, SO₂R⁶¹, COOR⁶¹, CONR⁶¹R⁶² or SO₂NR⁶¹R⁶² group, where:

R⁶¹ is a hydrogen atom or an optionally substituted, C₁₋₈ alkyl, C₂₋₈ alkynyl, C₂₋₈ alkenyl, C₃₋₈ cycloalkyl, aryl, heteroaryl or C₄₋₈ heterocyclic group; and

R⁶² is a hydrogen atom or an optionally substituted, C₁₋₈ alkyl, C₂₋₈ alkynyl, C₂₋₈ alkenyl, C₃₋₈ cycloalkyl, aryl, heteroaryl or C₄₋₈ heterocyclic group; and

when R⁶¹ and R⁶² are the same or different alkyl groups, they are, optionally, joined together to form a carbocyclic or heterocyclic ring system;

wherein, the optional substituents are defined the same as for the one or more substituents of formula (I) above.

28. (Currently amended) The compound ~~or pharmaceutical composition~~ according to claim 27, where, R³ is an optionally substituted, hydroxyaryl, alkoxyaryl or aminosulfonylaryl group, wherein, the optional substituents are defined the same as for the one or more substituents of formula (I) above.

29. (Currently amended) The compound ~~or pharmaceutical composition~~ according to claim 27, where, R⁹ is a hydrogen atom.

30. (Currently amended) The compound ~~or pharmaceutical composition~~ according to claim 27, where, one of R¹⁰ and R¹¹ is a hydrogen atom, and the other one of R¹⁰ and R¹¹ is a hydrogen atom or a hydroxy group.

31. (Currently amended) A method for treating a physiological disorder, symptom or disease in a patient, comprising administering to the patient an effective amount of the compound ~~or pharmaceutical composition~~ according to claim 1, wherein the physiological disorder, symptom or disease is urogenital, cardiovascular, cerebrovascular, peripheral vascular, angina pectoris, hypertension, restenosis post angioplasty, endarterectomy, stent introduction, cerebral stroke, respiratory tract, allergic conditions associated with atopy, pulmonary hypertension, ischemic heart disease, impaired glucose tolerance, diabetes and its related complications, insulin resistance syndrome, hyperglycemia, polycystic ovarian syndrome, glomerular [,.] renal insufficiency, nephritis, tubular interstitial, autoimmune, glaucoma, intestinal motility, cachexia or cancer.

32. (Original) The method according to claim 31, wherein the physiological disorder is a urogenital disorder.

33. (Original) The method according to claim 32, wherein the urogenital disorder is an erectile dysfunction.

34. (Currently amended) A method for elevating a cGMP level in a patient in need of the treatment, comprising administering to the patient an effective amount of the compound ~~or pharmaceutical composition~~ according to claim 1.

35. (Currently amended) A method for treating an erectile dysfunction in a patient in need of the treatment, comprising administering to the patient an effective amount of at least one of the compound ~~or pharmaceutical composition~~ according to claim 1.

36. (Canceled)

37. (Currently amended) A method for treating an erectile dysfunction in a patient in need of the treatment, comprising administering to the patient an effective amount of at least one of the compound ~~or pharmaceutical composition~~ according to claim 27.

38. (Canceled)

39. (Currently amended) A method for treating an erectile dysfunction and/or or another symptom, disease or disorder in a patient in need of the treatment, comprising administering to the patient a combination therapy, comprising an a


therapeutically effective amount of at least one of the compound or pharmaceutical composition according to claim 1 and at least one compound selected from the group consisting of: a prostanoid, α -adrenergic receptor, dopamine receptor agonist, melanocortin receptor agonist, endothelin receptor antagonist, endothelin converting enzyme inhibitor, angiotensin II receptor antagonist, angiotensin converting enzyme inhibitor, neutral metalloendopeptidase inhibitor, renin inhibitor, serotonin 5-HT_{2c} receptor agonist, nociceptin receptor agonist, rho kinase inhibitor, potassium channel modulator and multidrug resistance protein 5 inhibitor.

40. (Currently amended) A method for producing a compound having the formula (I), comprising:

(i) reacting a compound having the formula (III) with an alkyl halide in the presence of a base to form a compound having the formula (IV):

(III)

(IV)



where,


(a) R¹ is a hydrogen atom or a C₁₋₁₅ alkyl group, branched or straight chain, with or without unsubstituted or substituted with one or more substituents, a C₂₋₁₅ alkenyl group, branched or straight chain, with or without unsubstituted or substituted with one or more substituents, a C₂₋₁₅ alkynyl group, branched or straight chain, with or without unsubstituted or substituted with one or more substituents, a C₃₋₁₅ cycloalkyl group, with or without unsubstituted or substituted with one or more substituents, an arylalkyl group, with or without unsubstituted or substituted with one or more substituents, an

more substituents, an aryl group, ~~with or without~~ unsubstituted or substituted with one or more substituents, a heteroaryl group, ~~with or without~~ unsubstituted or substituted with one or more substituents, -OR⁵, -COOR⁵, -C(O)R⁵ or -C(O)N(R⁵)₂, where R⁵ is a hydrogen atom or a hydrocarbon radical, branched or straight-chain, ~~with or without~~ unsubstituted or substituted with one or more substituents;

(b) L is R^2 or a protected form of R^2 ; and

(c) Ph is a phenyl group;

(ii) debenzylating and then alkylating the compound having the formula (IV) with an alkyl halide having the formula XCH_2R^3 to form the compound having the formula (V):




where,

X is a halogen atom and

R^3 is an aryl group, with or without unsubstituted or substituted with one or more substituents, a heteroaryl group, with or without unsubstituted or substituted with one or more substituents, or a heterocyclic group having 1 to 3 heteroatoms fused to a 5- or 6-membered aryl ring, with or without unsubstituted or substituted with

one or more substituents, with the proviso that R^3 is not an aryl group substituted at its para position with a -Y-aryl group, where Y is a carbon-carbon single bond, -CO-, -O-, -S-, -N(R^{21})-, -CON(R^{22})-, -N(R^{22})CO-, -OCH₂-, -CH₂O-, -SCH₂-, -CH₂S-, -NHC(R^{23})(R^{24})-, -NR²³SO₂-, -SO₂NR²³-, -C(R^{23})(R^{24})NH-, -CH=CH-, -CF=CF-, -CH=CF-, -CF=CH-, -CH₂CH₂-, -CF₂CF₂-,



where,

R^{21} is a hydrogen atom or a -CO(C₁₋₄ alkyl), C₁₋₆ alkyl, allyl, C₃₋₆ cycloalkyl, phenyl or benzyl group;

R^{22} is a hydrogen atom or a C₁₋₆ alkyl group;

R^{23} is a hydrogen atom or a C₁₋₅ alkyl, aryl or -CH₂-aryl group;


R^{24} is a hydrogen atom or a C₁₋₄ alkyl group;

R^{25} is a hydrogen atom or a C₁₋₈ alkyl, C₁₋₈ perfluoroalkyl;

C₃₋₆ cycloalkyl, phenyl or benzyl group;

R^{26} is a hydrogen atom or a C₁₋₆ alkyl, C₃₋₆ cycloalkyl, phenyl or benzyl group;


R^{27} is -NR²³R²⁴, -OR²⁴, -NHCONH₂, -NHCSNH₂,



and

R^{28} and R^{29} are, independently of one another, each a C_{1-4} alkyl group, or R^{28} and R^{29} , taken together with each other, are a $-(CH_2)_q$ group, where q is 2 or 3; wherein, R^{21} through R^{29} are optionally substituted with one or more substituents; and


(iii) deprotonating and then halogenating the compound having the formula (V) to form a compound having the formula (VI):



where,

Hal is a halogen atom;

(iv) reacting the compound having the formula (VI) with an amine having the formula R^4NH_2 to form a compound having the formula (VII):




where,

R^4 is a C_{3-15} -cycloalkyl group, with or without one or more substituents, a C_{3-15} -cycloalkenyl group, with or without one or more substituents or a heterocycloalkyl group of 3 to 15 members, with or without unsubstituted or substituted with one or more substituents; and

(v) removing the protecting portion of L, when L is the protected form of R^2 , on the compound having the formula (VII) to form the compound having the formula (I):

(1)




where.

R^2 is defined the same as R^1 above, with the proviso that at least one of R^1 and R^2 is not a hydrogen atom; wherein, the one or more substituents for all the groups are chemically-compatible and are, independently of one another, each an: alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, arylalkyl, alkylaryl,

aryl, heteroaryl, heterocycloalkyl, hydroxyalkyl, arylalkyl, aminoalkyl, haloalkyl, thioalkyl, alkylthioalkyl, carboxyalkyl, imidazolylalkyl, indolylalkyl, mono-, di- and trihaloalkyl, mono-, di- and trihaloalkoxy, amino, alkylamino, dialkylamino, alkoxy, hydroxy, halo, nitro, oximino, $-\text{COOR}^{50}$, $-\text{COR}^{50}$, $-\text{SO}_{0-2}\text{R}^{50}$, $-\text{SO}_2\text{NR}^{50}\text{R}^{51}$, $\text{NR}^{52}\text{SO}_2\text{R}^{50}$, $=\text{C}(\text{R}^{50}\text{R}^{51})$, $=\text{N}-\text{OR}^{50}$, $=\text{N}-\text{CN}$, $=\text{C}(\text{halo})_2$, $=\text{S}$, $=\text{O}$, $-\text{CON}(\text{R}^{50}\text{R}^{51})$, $-\text{OCOR}^{50}$, $-\text{OCON}(\text{R}^{50}\text{R}^{51})$, $-\text{N}(\text{R}^{52})\text{CO}(\text{R}^{50})$, $-\text{N}(\text{R}^{52})\text{COOR}^{50}$ or $-\text{N}(\text{R}^{52})\text{CON}(\text{R}^{50}\text{R}^{51})$ group, where:

R^{50} , R^{51} and R^{52} are, independently of one another, each a hydrogen atom or a C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{4-6} heterocycloalkyl, heteroaryl and aryl group, or R^{50} and R^{51} are joined together to form a carbocyclic or heterocyclic ring system, or R^{50} , R^{51} and R^{52} are, independently of one another, each:



where,

R^{40} and R^{41} are, independently of one another, each a hydrogen atom or an alkyl, cycloalkyl, heterocycloalkyl, halo, aryl, imidazolylalkyl, indolylalkyl, heteroaryl, arylalkyl, arylalkoxy, heteroarylalkyl, heteroarylalkoxy, aminoalkyl, haloalkyl, mono-, di- or trihaloalkyl, mono-, di- or trihaloalkoxy, nitro, cyano, alkoxy, hydroxy, amino, phosphino, phosphate, alkylamino, dialkylamino,

formyl, alkylthio, trialkylsilyl, alkylsulfonyl, arylsulfonyl, alkylsulfinyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, morpholino, thioalkyl, alkylthioalkyl, carboxyalkyl, oximino, -COOR⁵⁰, -COR⁵⁰, -SO₀₋₂R⁵⁰, -SO₂NR⁵⁰R⁵¹, -NR⁵²SO₂R⁵⁰, -CON(R⁵⁰R⁵¹), -OCON(R⁵⁰R⁵¹), -N(R⁵²)CO(R⁵⁰), -N(R⁵²)COOR⁵⁰, -N(R⁵²)CON(R⁵⁰R⁵¹) or -OCONR⁵⁰ group, where, R⁵⁰, R⁵¹ and R⁵² are defined the same as above;


R⁴² is a hydrogen atom or an alkyl, alkenyl, arylalkyl or acyl group; and

R⁴³ is a hydrogen atom or an alkyl or aryl group;

where, R⁴⁰ through R⁴³ and R⁵⁰ through R⁵² are, independently of one another, each optionally substituted with any one of the groups defined above for the one or more substituents.

41. (New) A pharmaceutical composition comprising a compound, enantiomer, stereoisomer, rotomer or tautomer of claim 1 or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

42. (New) The compound according to claim 1, which is:



or

